Comparative Pharmacology
Head-to-head clinical analysis: AUKELSO versus LUZU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUKELSO versus LUZU.
AUKELSO vs LUZU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of the mammalian target of rapamycin (mTOR) kinase, specifically the mTORC1 complex, leading to inhibition of cell proliferation, angiogenesis, and glucose uptake.
Luliconazole inhibits fungal lanosterol 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
400 mg orally twice daily with food.
Apply a thin layer of luliconazole 1% cream to the affected skin once daily for 2 weeks (tinea pedis), 1 week (tinea cruris, tinea corporis).
None Documented
None Documented
Terminal elimination half-life approximately 24 hours (range 20–28 h), supports once-daily dosing; prolonged in severe hepatic impairment.
The terminal elimination half-life is approximately 140 hours (range 130-177 hours); this long half-life supports once-daily dosing and provides sustained drug concentrations in the skin following topical application.
Primarily hepatic metabolism with biliary excretion; ~20% renal elimination of unchanged drug. Fecal excretion of metabolites accounts for ~65% of total clearance.
Luliconazole is primarily eliminated via hepatic metabolism; renal excretion accounts for less than 1% of the dose; fecal excretion accounts for approximately 78-82% of the administered dose as metabolites; biliary excretion is a minor route.
Category C
Category C
Topical Antifungal
Topical Antifungal